*/ $mainBody =<< function socbm(addsite){ var AddTitle=document.title; var AddURL=location.href; switch(addsite){ case 0: // AddToBookmarks.com ID:0 - an educational page on what Social Bookmarking is var AddSite = "http://www.addtobookmarks.com/socialbookmarking.htm?"; var AddUrlVar = "url"; var AddTitleVar = "title"; var AddNoteVar = ""; var AddReturnVar = ""; var AddOtherVars = ""; break case 1: // Blink ID:1 var AddSite = "http://www.blinklist.com/index.php?Action=Blink/addblink.php"; var AddUrlVar = "url"; var AddTitleVar = "title"; var AddNoteVar = "description"; var AddReturnVar = ""; var AddOtherVars = "&Action=Blink/addblink.php"; break case 2: // Del.icio.us ID:2 &v=3&noui=yes&jump=close var AddSite = "http://del.icio.us/post?"; var AddUrlVar = "url"; var AddTitleVar = "title"; var AddNoteVar = ""; var AddReturnVar = ""; var AddOtherVars = ""; break case 3: // Digg ID:3 var AddSite = "http://digg.com/submit?"; var AddUrlVar = "url"; var AddTitleVar = ""; var AddNoteVar = ""; var AddReturnVar = ""; var AddOtherVars = "&phase=2"; break case 5: // GOOGLE ID:5 var AddSite = "http://fusion.google.com/add?"; var AddUrlVar = "feedurl"; var AddTitleVar = ""; var AddNoteVar = ""; var AddReturnVar = ""; var AddOtherVars = ""; break case 6: // Simpy ID:6 var AddSite = "http://simpy.com/simpy/LinkAdd.do?"; var AddUrlVar = "href"; var AddTitleVar = "title"; var AddNoteVar = "note"; var AddReturnVar = "_doneURI"; var AddOtherVars = "&v=6&src=bookmarklet"; break case 8: // Spurl ID: 8 d.selection?d.selection.createRange().text:d.getSelection() var AddSite = "http://www.spurl.net/spurl.php?"; var AddUrlVar = "url"; var AddTitleVar = "title"; var AddNoteVar = "blocked"; var AddReturnVar = ""; var AddOtherVars = "&v=3"; break default: } // Build the URL var addtoFullURL = AddSite + AddUrlVar + "=" + AddURL + "&" + AddTitleVar + "=" + AddTitle + AddOtherVars ; if (AddNoteVar != "") {var addtoFullURL = addtoFullURL + "&" + AddNoteVar + "=" + AddTitle;} if (AddReturnVar != "") {var addtoFullURL = addtoFullURL + "&" + AddReturnVar + "=" + AddURL;} //self.location = addtoFullURL myRef = window.open(addtoFullURL,'sbWin','left=20,top=20,width=600,height=500,toolbar=1,resizable=1'); return true; } //-->


Press Release Distribution
Provided by Advanced PR from Majon.com





HEALTH ENHANCEMENT PRODUCTS RECEIVES APPROVAL TO
COMMENCE HIV AND CRP CLINICAL TRIAL IN CAMEROON


Dateline: May 1, 2006 ... Scottsdale, AZ
Contact Name: Howard R. Baer, Health Enhancement Products, Inc.
Contact Phone: 480-385-3800
E-mail: hrbaer@aol.com
Web Address: http://www.heponline.com


SCOTTSDALE, AZ - May 1, 2006 -­ Heath Enhancement Products, Inc.
(OTCBB: HEPI) announced today that it will commence two separate
clinical trials, one of which will study the possible effects of
the company's sole product, ProAlgaZyme (PAZ), on HIV. In particular,
the study will explore PAZ's potential to reduce viral loads in
patients with HIV. The other study will investigate PAZ's
potential effects on C-Reactive Protein (CRP) levels and the
inflammation process. Both studies are being conducted by Dr.
Julius E. Oben, Head of the Department of Biochemistry,
University of Yaounde in Cameroon. The study has been approved
by the University Teaching Hospital Review Board and the Cameroon
National Ethics Committee, as well as the Cameroon Ministry of
Health.

The specific objectives of the HIV study are as follows:

1. To study the potential effect of ProAlgazyme(TM) on
CD4 lymphocyte cell count over an 8-week period.

2. To study the potential effect of ProAlgazyme(TM) on
viral load over an 8-week period.

3. To study the potential effect of ProAlgazyme(TM) on
malonaldehyde (MDA) and thiol protein concentrations over
an 8-week period.

4. To study the potential effect of ProAlgazyme(TM) on
CRP levels in HIV/AIDS patients over an 8-week period.

5. To study the potential effect of ProAlgazyme(TM) on
total cholesterol, HDL-cholesterol and LDL-cholesterol of
HIV/AIDS patients over an 8-week period.

A CRP related trial will be conducted simultaneously to test
PAZ's potential to reduce C-Reactive Protein (CRP) levels. The
American Heart Association (AHA) reported this year that, "most
studies show that the higher the hs-CRP levels, the higher the
risk of developing heart attack." The current study will
investigate the potential of ProAlgaZyme to control inflammation
and promote cardiovascular benefits in overweight and obese
people. PAZ, when tested in lab animals, showed an ability to
reduce inflammation, versus aspirin. The study will be an eight-
week randomized, double-blind, placebo controlled clinical trial.

Howard R. Baer, Chairman of Health Enhancement Products stated,
"These trials are a logical next step, based upon the results of
our prior testing. We've been working towards these trials for
several years and we're now approximately ninety days away from
what we expect to be positive results. Dr. Oben, an extensively
published physician, has a long history of conducting clinical
trials and we feel we are in expert hands. We look forward to the
conclusions of Dr. Oben´s studies."

Dr. Julius E. Oben stated, "It is with great pleasure that the
Laboratory for Nutrition and Nutritional Biochemistry at
University of Cameroon has been chosen by HEPI to conduct its
ProAlgaZyme clinical trials. The role of natural products in
promoting immune enhancement is a growing trend and needs to be
further explored."

Dr. Oben continued, "ProAlgaZyme offers the unique potential of
enhancing one's own immune system. The outcome of these trials
will be watched with great anticipation by Cameroonian AIDS
researchers and the Cameroon Ministry of Health as a means to
provide a possible approach to a terrible disease."

Approximately 38 million people worldwide are living with HIV,
about 65% of who (25 million) are living in Sub-Saharan Africa,
the region of Africa where the University of Yaounde, Cameroon is
located. Considering the extremely high rate of HIV incidents in
the region, HEPI determined that Cameroon would be an ideal place
to conduct the HIV clinical trials.

About Health Enhancement Products, Inc.

Health Enhancement Products Inc. is a nutraceutical company
engaged in the development of a supplementary health-enhancing
product using only pure, all-natural ingredients. The company's
sole product is ProAlgaZyme, a phytopercolate that is produced
from an algae grown in 100% distilled water.

The algae from which ProAlgaZyme is derived produces a protein,
most likely as a means of protecting itself from exposure to
outside disease and harmful bacteria. The protein solution is
then drawn off, filtered, tested and bottled for consumption. In
addition to supporting a compromised immune system, recent
clinical studies indicate that ProAlgaZyme has potential weight
loss properties. ProAlgaZyme has also been shown in a clinical
study to have the potential to improve serum glucose management,
when combined with a diet low in refined carbohydrates and a
light exercise regimen.

For more information, please visit http://www.heponline.com

Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-
looking statements involve risks and uncertainties. A number of
factors could cause actual results to differ from those indicated
in the forward-looking statements, including clinical trial
results being different than the Company's anecdotal results and
the company's ability to fund its operations and market and sell
its ProAlgaZyme product. Such statements are subject to a number
of assumptions, risks and uncertainties. Readers are cautioned
that such statements are not guarantees of future performance and
that actual results or developments may differ materially from
those set forth in the forward-looking statements. The company
undertakes no obligation to publicly update or revise forward-
looking statements, whether as a result of new information or
otherwise.

Media Contact:
Howard R. Baer, Health Enhancement Products, Inc.
Phone: 480-385-3800
E-mail: hrbaer@aol.com

Add this page to
Blink   Del.icio.us   Digg   Google   Simpy   Spurl  

  Internet marketing and advertising from one of the most popular marketin gand advertising companies on the internet!
       Got Internet Marketing?

Write Press Releases | Press Releases | PR Strategy

EOT; $page = preg_replace("/PRESSRELEASE/",$mainBody,$page); $page = preg_replace("/METAKEYWORDS/",$pageKeywords,$page); $pageDescription = $pageDescription . "; Health Enhancement Products Receives Approval To Commence HIV And CRP Clinical Trial In Cameroon"; $page = preg_replace("/METADESCRIPTION/",$pageDescription,$page); $pageTitle = $pageTitle . "; Health Enhancement Products Receives Approval To Commence HIV And CRP Clinical Trial In Cameroon"; echo preg_replace("/PRTITLE/",$pageTitle,$page); ?>